Analysis of immune responses to attenuated alcelaphine herpesvirus 1 formulated with and without adjuvant. (2021)
Attributed to:
Development of a vaccination strategy for the control of malignant catarrhal fever
funded by
BBSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/j.jvacx.2021.100090
PubMed Identifier: 33912826
Publication URI: http://europepmc.org/abstract/MED/33912826
Type: Journal Article/Review
Volume: 8
Parent Publication: Vaccine: X
ISSN: 2590-1362